Aprepitant Triple Therapy for the Prevention of CINV in Nondrinking and Young Women Who Received Moderately Emetogenic Chemotherapy — CINV  

Gastrointestinal Neoplasms Clinical Trial

Official title: Efficacy of Aprepitant for the Prevention of Chemotherapy-induced Nausea and Vomiting in Nondrinking Women Younger Than 50 Years Who Received Moderately Emetogenic Chemotherapy: A Randomized, Double-blind, Phase Ⅲ Trial

Status Completed

Clinical Trial Summary

The purpose of this study is to study whether adding Aprepitant to Palonosetron and dexamethasone can further prevent the incidence and severity of nausea and vomiting caused by FOLFIRI or FOLFOX chemotherapy regimen among gastrointestinal malignancy patients with high risk factors of chemotherapy-associated adverse events.

Clinical Trial Description

The purpose of this study is to study whether adding Aprepitant to Palonosetron and dexamethasone can further prevent the incidence and severity of nausea and vomiting caused by FOLFIRI or FOLFOX chemotherapy regimen after curative effect among gastrointestinal malignancy patients with high risk factors of chemotherapy-associated adverse events.This study will observe and evaluate the incidence and severity of nausea and vomiting as well as the effectiveness of corresponding treatment(with or without Aprepitant) during Day 1 to Day 5 from the beginning of chemotherapy. ;

Related Conditions & MeSH terms

• Chemotherapy-induced Nausea and Vomiting
• Digestive System Neoplasms
• Gastrointestinal Neoplasms
• Nausea
• Vomiting

• NCT number: NCT03674294
• Study type: Interventional
• Source: Sun Yat-sen University
• Status: Completed
• Phase: Phase 3
• Start date: August 4, 2015
• Completion date: June 1, 2020